

# Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration

NCT07040137

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Kissei Pharmaceutical Co., Ltd.
Enrollment	142 participants

## Key Eligibility Criteria

---

### Inclusion (1)

- Japanese SCD patients with mild to moderate ataxia

### Exclusion (2)

- Patients with secondary ataxia
- Patients with clinically significant hepatic, renal, or cardiovascular dysfunction

## Locations (1 total)

---

Research Site, Multiple Locations, Japan